Insights from CDMO Live Europe 2026 reveal why the next generation of CDMO leaders will be defined by integration, execution, and strategic alignment rather than scale alone
The conversations at CDMO Live Europe 2026 made one reality unequivocally clear: uncertainty is no longer episodic- it is structural.
However, when these insights are viewed alongside Frost & Sullivan’s latest CDMO growth opportunity analysis, a more important conclusion emerges: Uncertainty is not suppressing growth, it is concentrating it into a defined set of high-value capabilities across biologics and small molecule outsourcing.
The CDMO industry is no longer in a broad expansion cycle, it is in a precision growth phase.
From Broad Outsourcing to Targeted Capability Demand
Across discussions with leaders from Takeda, Johnson & Johnson, and UCB, a structural shift is evident:
- Fewer CDMO partners, but deeper engagement
- Higher expectations on execution, speed, and transparency
- Increased prioritisation of integrated and specialised capability platforms
➡️ Strategic Implication: Growth will accrue to CDMOs that solve specific bottlenecks, not those that expand capacity indiscriminately.
Growth Opportunity 1: Integrated ADC, HPAPI & Sterile Injectables- The Convergence of High-Value Manufacturing
The most powerful convergence across both Frost & Sullivan studies and CDMO Live discussions is the rapid emergence of integrated high-potency, biologics, and sterile manufacturing ecosystems.
This includes:
- ADC upstream biologics manufacturing
- HPAPI and payload/linker manufacturing
- Sterile fill‑finish and injectable delivery platforms
At CDMO Live, these themes were consistently reinforced:
- BSP Pharmaceuticals highlighted containment as a system-level capability across ADC workflows
- Simtra BioPharma and Eramol showcased flexible, Annex 1-compliant injectable capacity
- Sharp pointed to packaging and supply bottlenecks in injectable therapies (e.g., GLP‑1 demand)
Meanwhile, strategic investments from Lonza, Cerbios and Cambrex in HPAPI and bioconjugation capabilities highlight strong industry alignment with this trend.
➡️ Frost & Sullivan Perspective: The fastest-growing and most supply-constrained segment in CDMOs is no longer a single capability- but the integration of ADC, HPAPI, and sterile injectable manufacturing into end-to-end platforms.
This convergence is being driven by:
- oncology pipeline expansion
- increasing therapy complexity
- regulatory demands for containment and sterility
- sponsor preference for fewer, fully integrated partners
CDMOs such as Boehringer Ingelheim, Rentschler Biopharma SE and ProBioGen AG are also strengthening capabilities across biologics manufacturing, high-potency systems, and integrated development-to-commercialisation platforms, further reinforcing the shift toward end-to-end CDMO ecosystems.
➡️ Strategic Implication: CDMOs that build end-to-end high-potency + biologics + fill‑finish ecosystems will capture disproportionate share of future outsourcing value.
Growth Opportunity 2: Biosimilars- Scaling with Strategic Relevance
Frost & Sullivan identifies biosimilar manufacturing as a key biologics growth vector, driven by:
- patent expirations
- healthcare cost pressures
- expanding global access
At CDMO Live, this opportunity is evolving beyond cost arbitrage into:
- regional supply security strategies
- long-term outsourcing partnerships
- platform-based manufacturing approaches
Companies such as:
- Sandoz
- Biocon Biologics
- Fujifilm Diosynth Biotechnologies
are aligning around scale, efficiency, and regionalisation.
➡️ Frost & Sullivan Perspective: Biosimilars are transitioning from volume-led growth to strategic, resilience-driven manufacturing platforms. CDMOs such as mAbxience, AGC Biologics, and 3PBIOVIAN are playing an increasingly important role in advancing biosimilar manufacturing capacity, supporting regional supply strategies and scalable biologics production platforms.
➡️ Strategic Implication: CDMOs that build cost-efficient, platform-driven biosimilar manufacturing with strong regional presence (EU/NA/APAC) will secure long-term, high-volume partnerships, as sponsors prioritise supply continuity, regulatory reliability, and lifecycle cost optimisation over short-term outsourcing decisions.
Growth Opportunity 3: Complex Oral Solids & Advanced Formulation- The Hidden Value Engine
The small molecule CDMO analysis highlights a critical but often underappreciated growth area:
- complex oral solid dosage forms (FDF)
- solubility enhancement and bioavailability technologies
- particle engineering and formulation innovation
While less visible in CDMO Live discussions, this segment represents a high-margin, differentiation-driven opportunity, as pipelines increasingly include poorly soluble and formulation-sensitive molecules.
Companies such as:
- Recipharm
- Blue Jet Healthcare
are expanding into:
- advanced formulation platforms
- integrated development + commercial manufacturing
- differentiated delivery systems
➡️ Frost & Sullivan Perspective: Formulation science is emerging as a critical lever for value creation in small molecule outsourcing. CDMOs including Bora Pharmaceutical Services and Curia Global, Inc. are expanding their footprint in complex small molecule development and formulation, particularly in areas requiring specialised process development, scalability, and differentiated drug product capabilities.
➡️ Strategic Implication: CDMOs with proprietary formulation technologies and integrated FDF development capabilities will capture premium, high-margin programmes, as sponsors increasingly seek partners that can solve bioavailability challenges and accelerate clinical-to-commercial translation for complex small molecules.
The Enabler Layer: Partnership Models Are Lagging Behind Opportunity
A central CDMO Live takeaway: ~80% of stakeholders aim for strategic partnerships but execution remains inconsistent.
Key challenges:
- misaligned incentives
- rigid pricing models
- fragmented governance
Frost & Sullivan analysis reinforces the need for:
- risk-sharing models
- integrated CRDMO structures
- digitally enabled collaboration
Companies such as Recipharm and Blue Jet Healthcare highlighted emerging co-investment and partnership frameworks.
➡️ Frost & Sullivan Perspective: Growth opportunities will only be realised where partnership models evolve alongside capabilities.
Execution Excellence: The Multiplier Across All Growth Areas
One of the most candid CDMO Live insights:
“Most failures are not capability failures, but execution failures.”
Across both Frost & Sullivan studies:
- digital integration
- operational visibility
- speed and reliability
are becoming baseline expectations.
➡️ Frost & Sullivan Perspective: Even in high-growth segments like ADCs or biosimilars, execution determines who captures value.
Regionalisation & Resilience: Redefining Where Growth Happens
Both CDMO Live and Frost & Sullivan analysis emphasise:
- localised manufacturing in NA and EU
- multi-regional production networks
- policy-driven supply chain shifts
Discussions involving BioDuro and others reinforced the importance of:
- early-stage alignment
- lifecycle partnership continuity
- geopolitical adaptability
➡️ Frost & Sullivan Perspective: CDMOs combining global scale with local execution will dominate future outsourcing decisions.
Key Takeaway: Growth Will Be Won by Integration, Not Scale
The CDMO industry is not facing a demand shortage, it is facing a precision allocation of demand.
The New CDMO Growth Equation = Capability Integration × Execution Excellence × Partnership Alignment × Regional Resilience
Winners will not be those who:
- expand capacity alone
- compete on cost alone
They will be those who:
- integrate high-value capabilities across modalities
- deliver execution-led partnerships
- invest in differentiated, supply-constrained segments
- align with global supply chain realities
In an uncertain world, the next generation of CDMO leaders will be defined not by size but by their ability to integrate, execute, and align.
Study Citations
- Frost & Sullivan – Growth Opportunities in Biologics Contract Development & Manufacturing Organizations, Global, 2026–2031 (M1H8) https://store.frost.com/growth-opportunities-in-biologics-contract-development-manufacturing-organizations-global-2026-2031.html
- Frost & Sullivan – Growth Opportunities in Small Molecule Contract Development & Manufacturing Organizations, Global, 2026–2031 (M1K4…upcoming)
